Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04189-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Tzu-Hui Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Sheng-Li Rd, Tainan City…. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Protein Serine-Threonine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Science and Technology of Taiwan, National Cheng Kung University Hospital, National Cheng Kung University.
Abstract (Originalsprache)
The tumor microenvironment in breast cancer is typically immunosuppressive. Combined neoadjuvant chemotherapy and immunotherapy is the standard of care for high-risk, triple-negative breast cancer patients, but it is not routinely applied to other breast cancer subtypes. Somatic mutation of STK11 (serine/threonine kinase 11), a tumor suppressor, occurs in the MSK-IMPACT platform in 1.9% of 3116 breast cases. A potential link between inactivation of STK11 and immune response regulation has been suggested in breast cancer, but the impact of STK11 suppression on tumor–immune interactions remains under investigation. In this study, we established Stk11 -knockout ( Stk11 -KO) mouse breast cancer cell lines, performed RNA sequencing and cytokine array analysis to assess alterations in gene expression and cytokine profiles. Our results revealed significant enrichment of several immune-related pathways and a marked increase in C-X-C motif chemokine ligand 1 (Cxcl1) expression in response to Stk11 knockout. Moreover, analysis of breast cancer patient samples showed an inverse association between the plasma CXCL1 levels and STK11 expression. To evaluate the in vivo effects of STK11 loss, we established an orthotopic breast cancer model in immunocompetent female mice. Tumors derived from Stk11 -KO mouse breast cancer cells demonstrated greater tumorigenicity. In addition, mice-bearing Stk11 -KO tumors exhibited elevated levels of circulating polymorphonuclear myeloid-derived suppressive cells. In summary, STK11 suppression enhances immune-related pathways and promotes Cxcl1 expression, correlating with the expansion of immunosuppressive MDSC populations. Our findings suggest that targeting STK11-associated immunosuppressive mechanisms may provide a novel therapeutic option for STK11 -deficient breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Sheng-Li Rd, Tainan City, 704302, Taiwan.
- School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704302, Taiwan.
- Center of Applied Nanomedicine, College of Medicine, National Cheng Kung University, Tainan, 701401, Taiwan.
- Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, No. 60, Sec. 1, Erren Rd., Rende Dist., Tainan City, 717301, Taiwan. s5887110@mail.cnu.edu.tw.
- Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Sheng-Li Rd, Tainan City, 704302, Taiwan. hphsu@mail.ncku.edu.tw.
Förderung
- The Ministry of Science and Technology of Taiwan
- National Cheng Kung University Hospital
- National Cheng Kung University
- E-Da Hospital
- Chi Mei Medical Center
Zitieren
APA
Wei, T. H., Hsieh, C. C., Loh, Z. J., Chung, W. P., Lee, K. T., Chen, Y. L., Hsu, H. P., & Shen, C. H. (2025). Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04189-8
Vancouver
Wei TH, Hsieh CC, Loh ZJ, Chung WP, Lee KT, Chen YL, et al. Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04189-8
BibTeX
@article{Wei2025,
author = {Wei, Tzu-Hui and Hsieh, Chi-Che and Loh, Zhu-Jun and Chung, Wei-Pang and Lee, Kuo-Ting and Chen, Yi-Ling and Hsu, Hui-Ping and Shen, Che-Hung},
title = {Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04189-8}
}
EUVIMED